When the Grinfeld algorithm was applied, 87% of patients presenting with SVT corresponded to MPN with heterozygous JAK2 mutation, a molecular group that is associated with a better survival and a lower rate of disease progression. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.